Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
Virpax Pharmaceuticals (NASDAQ: VRPX) has appointed Destum Partners as its exclusive advisor for global partnering and licensing efforts, focusing on two OTC products: Epoladerm for osteoarthritis pain and AnQlar as a viral barrier. Destum will also assist in finding a partner for Probudur, an Rx product for postoperative pain management. CEO Anthony Mack emphasized the need for specialized transactional experience to maximize shareholder value. Destum aims to develop opportunities around Virpax's innovative drug-delivery systems targeting pain and CNS disorders.
- Appointment of Destum Partners to enhance global partnering efforts.
- Focus on two promising OTC products, Epoladerm and AnQlar.
- Engagement for identifying partners in the animal health market for Probudur.
- None.
“We have engaged
“Virpax is developing exciting innovative and proprietary drug-delivery systems across various pain and CNS disorder indications as well as a product candidate intended as a viral barrier for Covid and influenza. We look forward to working alongside the Virpax team in developing, partnering and licensing opportunities for what we believe to be a strong pipeline of drug product candidates,” commented
About
About
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol™ is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights to NobrXiol. Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit www.virpaxpharma.com.
Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors, including the Company’s ability to successfully complete research and further development and commercialization of Company drug candidates in current or future indications; the uncertainties inherent in clinical testing; our ability to manage and successfully complete clinical trials and the research and development efforts for multiple product candidates at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the timing, cost and uncertainty of obtaining regulatory approvals for our product candidates; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete clinical trials that we plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q that we file with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005174/en/
Chief Financial Officer
cchipman@virpaxpharma.com
610-727-4597
Or
betsy.brod@affinitygrowth.com
212-661-2231
Source:
FAQ
What is the significance of Virpax engaging Destum Partners for VRPX?
What OTC product candidates is Virpax focusing on with Destum Partners?
How will Destum Partners assist Virpax Pharmaceuticals?